News | 25 April 2026
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
The capacity addition to be implemented in a phased manner amid evolving business and market dynamics
Shares issued under ESOP 2008 and MESOP 2018 plans following exercise of vested stock options, in compliance with SEBI disclosure norms
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Growth was broad-based across segments
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio
New formulation by Greenspace Herbs to target improved efficacy and lower dosage in curcumin supplements
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
It is actually a new ISO Class 5 controlled cleanroom designed to deliver washed, dried, and gamma-sterilized single-use assemblies ready for immediate use.
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Targets high-growth eye care expansion push
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
Analysts expect modest revenue growth but pressure on profitability in the March quarter
PMDA is regarded among the most stringent regulatory bodies globally
The dispute stems from an earlier circular by Zuventus allegedly accusing Zorvia of market sabotage
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
Subscribe To Our Newsletter & Stay Updated
